Biografia
Dr Jürgen Frevert is Head of Botulinum Toxin Research at Merz Pharmaceuticals GmbH, in Potsdam, Germany. Between 1995 and 2006, Dr Frevert was Project Manager for biochemical projects and later Chief Scientific Officer of BioteCon Therapeutics GmbH, and during this time he was responsible for the development of NT101/NT201 (licensed as Bocouture®). Dr Frevert is trained in chemistry and biochemistry and has published articles in the scientific and medical literature.
